TORONTO, Sept. 20, 2018 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the voting results from the Company's annual meeting of shareholders held today, September 20, 2018 in Toronto (the "Meeting"). A total of 53.51% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
Medicenna is pleased to announce that all of the nominees listed in the management proxy circular dated August 20, 2018 were elected as directors. Each of the directors was elected with greater than 99% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:
% of Votes For
% of Votes Withheld
Dr. Fahar Merchant
Mr. Albert Beraldo
Dr. William Li
Ms. Rosemina Merchant
Dr. Chandrakant Panchal
Mr. Andrew Strong
Medicenna shareholders also voted to re-appoint Davidson & Company LLP as auditor of the Company.
Medicenna is a clinical stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs). Our mission is to become the leader in the development and commercialization of ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases. MDNA55 is Medicenna's lead EC currently enrolling in a multi-centre Phase 2 clinical trial for the treatment of recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. MDNA55 has secured Orphan Drug Status from the United States Food and Drug Administration (FDA) and the European Medicines Agency as well as Fast Track Designation from the FDA for the treatment of rGBM. For more information, please visit www.medicenna.com.
SOURCE Medicenna Therapeutics Corp.